Tumor heterogeneity and acquired drug resistance in FGFR2-fusion-positive cholangiocarcinoma through rapid research autopsy

Cholangiocarcinoma is a highly aggressive and lethal malignancy, with limited treatment options available. Recently, FGFR inhibitors have been developed and utilized in FGFR-mutant cholangiocarcinoma; however, resistance often develops and the genomic determinants of resistance are not fully charact...

Descripción completa

Detalles Bibliográficos
Autores principales: Krook, Melanie A., Bonneville, Russell, Chen, Hui-Zi, Reeser, Julie W., Wing, Michele R., Martin, Dorrelyn M., Smith, Amy M., Dao, Thuy, Samorodnitsky, Eric, Paruchuri, Anoosha, Miya, Jharna, Baker, Kaitlin R., Yu, Lianbo, Timmers, Cynthia, Dittmar, Kristin, Freud, Aharon G., Allenby, Patricia, Roychowdhury, Sameek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory Press 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6672025/
https://www.ncbi.nlm.nih.gov/pubmed/31371345
http://dx.doi.org/10.1101/mcs.a004002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6672025/
https://www.ncbi.nlm.nih.gov/pubmed/31371345
http://dx.doi.org/10.1101/mcs.a004002

Ejemplares similares